Challenging federal funding cuts, minimal residual disease, and a busy field of CAR T-cell candidates characterized this year ...

At SABCS, Mayo Clinic researchers reported PRS data was more likely to change the risk categories of people with variants in moderate risk penetrance genes.

The firm is testing the EGFR inhibitor BH-30643 in EGFR-mutated NSLC and the CLK inhibitor in certain blood cancers.

Waskyra, developed by Fondazione Telethon, is the first gene therapy that the FDA has approved from a non-profit applicant.

Patient drug sensitivity profiles were linked to their genomic mutation profiles and could provide prognostic and survival data.

NEW YORK – A gene therapy using lentiviral particles to generate CAR T cells inside multiple myeloma patients has shown the ability to eliminate the small number of cancer cells in the bone marrow ...

Researchers also discussed access barriers at the meeting, and a survey found distance was a major hindrance to CAR-T ...

Writing in JAMA, regulators said randomized controlled trials with a survival or time-to-event endpoint would be expected for approval of a new CAR T-cell therapy.

An expert panel now recommends using certain personalized therapies in the frontline setting for older adults with FLT3- and IDH1-mutant disease.

Studies presented at the American Society of Hematology's annual meeting investigated the use of circulating tumor cells to assess the risk of progression in multiple myeloma patients.

The firm plans to seek accelerated approval from the FDA next year, while it launches a Phase III trial to support other regulatory applications.

Researchers have given the gene therapy made at UManchester to two out of five planned patients in a Phase I/II trial, and ...